AChE-IN-63 

AChE-IN-63 (Compound 5AD) is a selective inhibitor of hAChE (IC₅₀=0.103 μM). AChE-IN-63 also inhibits hBChE and hBACE-1 (IC₅₀= 10 μM (hBChE); 1.342 μM (hBACE-1)). AChE-IN-63 inhibits Aβ aggregation, preventing the formation and deposition of Aβ1-42. AChE-IN-63 can effectively penetrate the blood-brain barrier and is orally effective. It is primarily used in Alzheimer's disease research^[1].

AChE-IN-63 (5-20 μM; 48 h) inhibits Aβ1-42 aggregation in a concentration-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

AChE-IN-63 (p.o.; 100 mg/kg; single dose) exhibits no toxicity or abnormal reactions in Swiss albino mice^[1].
AChE-IN-63 (p.o.; 5-20 mg/kg; single dose) improves learning and memory in cognitive dysfunction mice in the Scopolamine (HY-N0296) Y-Maze Model and demonstrates good antioxidant properties^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

321.38

C₁₈H₁₉N₅O

876685-78-8

C1(C2=NN=C(O2)CN3CCN(CC3)C4=CC=CC=N4)=CC=CC=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Singh A, et al. Structure-Guided Design, Synthesis, and Biological Evaluation of Peripheral Anionic Site Selective and Brain Permeable Novel Oxadiazole-Piperazine Conjugates against Alzheimer's Disease with Antioxidant Potential. ACS Omega. 2024 Apr 11;9(16):18169-18182.  [Content Brief]